UNSPSC 51381501: Colfenamate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H13F3N2O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier N0V0Q7845W, chemically known as n-(alpha, alpha, alpha-trifluoro-m-tolyl)anthranilic acid, ester with glycolamide. but more generally known as colfenamate, which bears U.S. National Institutes of Health Compound Identifier 198806. The European Medicines Agency schedules Colfenamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06797MIG.

The term COLFENAMATE is an International Non-Proprietary Name. COLFENAMATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: FC(F)(F)C1CC(NC2C(CCCC2)C(=O)OCC(=O)N)CCC1.

UNSPSC 51381501 Colfenamate is a Commodity code that nominally addresses a specific nonsteroidal anti-inflammatory drug, but recent state and local solicitations tagged with this code show minimal alignment with the code's pharmaceutical specificity. The recent opportunities instead reflect broader pharmaceutical procurement — naloxone and drug deactivation systems for public health response, direct-to-manufacturer prescription program design for state Medicaid and employee health plans, and multi-source generic pharmaceuticals distributed through cooperative purchasing networks. State and local governments use procurement tagged to this code to source emergency medications, pharmacy benefit administration capabilities, and generic drug supply agreements across health departments, human services agencies, and cooperative purchasing alliances that serve multiple jurisdictions.

The issuing-body mix includes single-jurisdiction health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and subordinate participating states and localities). The geographic spread spans Florida, Texas, and Minnesota with multistate participation through the MMCAP cooperative vehicle. Representative recent opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (response due July 26, 2023), Texas HHS Commission's RFI HHS0017013 soliciting vendor capabilities for direct-to-manufacturer prescription programs (response due April 3, 2026), and MMCAP's S1070000015802 RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with responses due March 26, 2026.